易瑞生物：与科汉森签订7305.77万欧元销售合同

Core Viewpoint - The company has signed a Partnership and Distribution Agreement with Chr.Hansen A/S, targeting a total sales goal of €73.0577 million (approximately ¥601 million) for the years 2025-2029, which is expected to positively impact the company's financial status and operational performance [1] Group 1: Agreement Details - The sales target for 2025 accounts for approximately 42.18% of the company's audited revenue for 2024 [1] - The agreement allows Chr.Hansen exclusive rights to sell, distribute, and promote the company's products in designated regions [1] - The contract will be effective from June 16, 2025, and will last for five years [1] Group 2: Product Focus - The main products involved in the agreement include antibiotic residue screening tests for milk, aflatoxin M1 screening and quantitative tests, melamine, and whey adulteration tests [1] Group 3: Strategic Impact - The partnership is expected to enhance the company's core competitiveness and market influence [1]